Profile data is unavailable for this security.
About the company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
- Revenue in USD (TTM)45.71m
- Net income in USD-103.57m
- Incorporated2008
- Employees121.00
- LocationEyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050
- Websitehttps://eyepointpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | 247.00m | -180.81m | 402.83m | 597.00 | -- | -- | -- | 1.63 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 411.21m | 135.00 | -- | -- | -- | 6.98 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 441.08m | 147.00 | 115.56 | -- | 76.07 | 2.80 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 447.49m | 45.00 | 5.28 | 2.64 | 5.19 | 2.58 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 452.96m | 377.00 | -- | -- | -- | 2.42 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 470.14m | 99.00 | -- | 2.55 | -- | 7.44 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 486.68m | 240.00 | -- | -- | -- | 1.65 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 487.32m | 65.00 | -- | 6.97 | -- | 19.66 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 509.33m | 1.60k | -- | 1.00 | -- | 0.4525 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 652.27m | -79.06m | 525.69m | 2.52k | -- | 0.6076 | -- | 0.8059 | -0.3017 | -0.3017 | 2.48 | 3.26 | 0.6062 | 4.98 | 36.38 | 259,248.20 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 548.67m | 76.00 | -- | 36.50 | -- | 239.00 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 45.71m | -103.57m | 568.60m | 121.00 | -- | 2.04 | -- | 12.44 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| CorMedix Inc | 12.26m | -46.15m | 626.80m | 82.00 | -- | 10.18 | -- | 51.12 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Phathom Pharmaceuticals Inc | 26.27m | -339.45m | 646.17m | 452.00 | -- | -- | -- | 24.60 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 71.17m | -6.39m | 659.87m | 64.00 | -- | 13.96 | -- | 9.27 | -0.0059 | -0.0059 | 0.0677 | 0.0443 | 0.8957 | 2.68 | 4.46 | 1,112,051.00 | -8.04 | 19.07 | -10.06 | 24.29 | 44.73 | 46.63 | -8.98 | 20.77 | 2.42 | 0.75 | 0.1634 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
Data as of Nov 21 2024. Currency figures normalised to EyePoint Pharmaceuticals Inc's reporting currency: US Dollar USD
69.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 30 Sep 2024 | 8.33m | 15.56% |
| Suvretta Capital Management LLCas of 30 Sep 2024 | 5.18m | 9.67% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 3.98m | 7.44% |
| Adage Capital Management LPas of 30 Sep 2024 | 3.79m | 7.08% |
| Federated Global Investment Management Corp.as of 31 Oct 2024 | 3.71m | 6.93% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.67m | 6.87% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.94m | 5.50% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.37m | 4.43% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 1.75m | 3.27% |
| Citadel Advisors LLCas of 30 Sep 2024 | 1.38m | 2.58% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
